Palabras clave
Anticuerpos monoclonals
Eficacia
Efectos secundarios y reacciones adversas relacionadas con medicamentos
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Revisar la eficacia y seguridad del fármaco pembrolizumab en el cáncer de mama triple negativo. Métodos: Revisión integrativa en las bases PUBMED, BVS y LILACS, con los descriptores “pembrolizumab and triple negative breast cancer” y términos alternativos en portugués, inglés y español, filtrando ensayos clínicos aleatorizados publicados en los últimos cinco años. Resultados: Se seleccionaron diecinueve artículos que describen la seguridad y eficacia del pembrolizumab en CMTN. El fármaco mostró mejores tasas de respuesta objetiva (ORR), supervivencia global (OS) y supervivencia libre de progresión (PFS) frente a la quimioterapia aislada. En cuanto a la seguridad, se observaron reacciones adversas de grado 1 y 2, lo que podría limitar su uso en pacientes con enfermedades autoinmunes, aunque se consideraron leves y controlables con corticosteroides y tratamiento de apoyo. Consideraciones finales: El pembrolizumab es una alternativa eficaz y segura para tratar el CMTN.
Referencias
ADAMS S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology 2019a; 30(3): 397–404.
ADAMS S, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology 2019b; 30(3): 405–11.
ANVISA. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Keytruda® (pembrolizumabe): nova indicação [Internet]. [citado 2023 nov 13]; Available from: https ://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/keytruda-r-pembrolizumabe-nova-indicacao-4.
ANDERS CK, et al. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. J Immunother Cancer, 2022; 10(2).
CHUN B, et al. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. J Immunother Cancer, 2022; 10(1).
CONITEC. Diretrizes diagnósticas terapêuticas: carcinoma de mama [Internet]. Brasília: Available from: https ://www.gov.br/conitec/pt-br. 2022.
CORTES J, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2022; 387(3): 217–26.
CORTES J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet, 2020; 396(10265): 1817–28.
DERAKHSHAN F e REIS-FILHO JS. Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2021; 17: 181–204.
EGELSTON CA, et al. Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunology, Immunotherapy, 2023; 72(9): 3013–27.
EISENHAUER EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009; 45(2): 228–47.
FASCHING PA, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer, 2023; 184: 1–9.
HATTORI M, et al. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355. Cancer Med, 2023; 12(9): 10280–93.
HO AY, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer, 2020; 126(4): 850–60.
HUANG M, et al. Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. European Journal of Cancer, 2022; 177: 45–52.
INCA. INSTITUTO NACIONAL DO CÂNCER. Síntese de Resultados e Comentários [Internet]. Available from: https ://www.gov.br/inca/pt-br/assuntos/cancer/numeros/estimativa/sintese-de-resultados-e-comentarios. 2023.
MERCK SHARP & DOHME FARMACÊUTICA LTDA. KEYTRUDA ® [Internet]. Available from: https ://saude.msd.com.br/wp-content/uploads/sites/91/2022/12/keytruda_bula_pro.pdf. 2023.
MORRIS GJ, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and caucasian patients: a single-institution compilation compared with the National Cancer Institute’s surveillance, epidemiology, and end results database. Cancer, 2007; 110(4): 876–84.
OLADERU OT, et al. Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer. JAMA Netw Open, 2020; 3(9): 2016247.
SCHMID P, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022; 386(6): 556–67.
SCHMID P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020a; 382(9): 810–21.
SCHMID P, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, 2020b; 31(5): 569–81.
SHAH M, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2022; 28(24): 5249–53.
TOLANEY SM, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib/II study. Clinical Cancer Research, 2021; 27(11): 3061–8.
TOPALIAN SL, et al. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 2015; 27(4): 450–61.
VASCONCELOS MC DE HV, et al. Evolução e desenvolvimento do tratamento farmacológico relativo ao câncer de mama triplo negativo: revisão integrativa. Research, Society and Development, 2023; 12(3): 6912340413.
VINAYAK S, et al. Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol, 2019; 5(8): 1132–40.
WEBER JS, et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist, 2016; 21(10): 1230–40.
WINER E, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-199): a randomised, open-label, phase 3 trial. The Lancet Oncology, 2021; 22(4): 499–511.
XU J. Regulation of cancer immune checkpoints [Internet]. In: Advances in Experimental Medicine and Biology. Available from: http ://www.springer.com/series/5584. 2020.
YIN L, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 2020; 22(1).
YUAN Y, et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist, 2021; 26(2): 99-217.